Please login to the form below

Not currently logged in
Email:
Password:

anti-inflammatory

This page shows the latest anti-inflammatory news and features for those working in and with pharma, biotech and healthcare.

Setback for AZ as tralokinumab flunks asthma trial

Setback for AZ as tralokinumab flunks asthma trial

Asthma affects 315m individuals worldwide, and up to 10% of asthma patients have severe asthma, which may be uncontrolled despite high doses of bronchodilator and anti-inflammatory medicines including chronic steroids.

Latest news

More from news
Approximately 1 fully matching, plus 127 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2015 Deal Watch October 2015

    Under the agreement Janssen has an option to license enGene's lead candidate, EG-12, for the gut-localised expression of the anti-inflammatory cytokine IL-10 in indications such as ... Up to 3 anti-PD-1 based bispecific antibodies for oncology. Expansion

  • Pharma deals during December 2014 Pharma deals during December 2014

    J&J has been busy entering into licences and research collaborations on the one hand, while exercising an opt-out and terminating its $945m anti-inflammatory deal with Astellas that was ... In early December, Merck added more weight to its

  • Investing in the future of R&D Investing in the future of R&D

    The anti-inflammatory TNF drug, whose indications currently include rheumatoid arthritis and Crohn's disease, became UCB's leading product in the first half of 2014, thanks to 23% growth in ... This was followed in March by a drug discovery and

  • Back to the future Back to the future

    The best-selling biologic - and still pharma's biggest global brand - is Humira, AbbVie and Eisai's anti-inflammatory drug.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    167. UCB/ Sanofi. Collaboration - discovery/ development. Anti-inflammatory small molecules for treatment of immune-mediated disorders (discovery). ... 23. Genmab/ Janssen. Milestone payment. Daratumumab, anti-CD38 mAb for multiple myeloma (p2 milestone).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics